Which has higher valuation and earnings, BBNX or INFU?

InfuSystem has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Beta Bionics $100.25M 7.53 -$73.20M -$1.51 N/A InfuSystem $142.40M 1.32 $870K $0.38 24.47

Is BBNX or INFU more profitable?

InfuSystem has a net margin of 1.12% compared to Beta Bionics' net margin of -60.27%. InfuSystem's return on equity of 2.78% beat Beta Bionics' return on equity. Company Net Margins Return on Equity Return on Assets Beta Bionics -60.27% -23.00% -20.55% InfuSystem 1.12% 2.78% 1.41%

Which has higher valuation & earnings, CBLL or INFU?

InfuSystem has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CeriBell $89.06M 8.32 -$53.41M -$1.63 N/A InfuSystem $142.40M 1.32 $870K $0.38 24.47

Is CBLL or INFU more profitable?

InfuSystem has a net margin of 1.12% compared to CeriBell's net margin of -63.51%. InfuSystem's return on equity of 2.78% beat CeriBell's return on equity. Company Net Margins Return on Equity Return on Assets CeriBell -63.51% -38.19% -30.92% InfuSystem 1.12% 2.78% 1.41%

Which has stronger earnings & valuation, SIBN or INFU?

InfuSystem has lower revenue, but higher earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SiBone $200.93M 3.94 -$18.90M -$0.39 N/A InfuSystem $142.40M 1.32 $870K $0.38 24.47

Is SIBN or INFU more profitable?

InfuSystem has a net margin of 1.12% compared to SiBone's net margin of -8.10%. InfuSystem's return on equity of 2.78% beat SiBone's return on equity. Company Net Margins Return on Equity Return on Assets SiBone -8.10% -9.56% -7.06% InfuSystem 1.12% 2.78% 1.41%

InfuSystem (INFU) Competitors

$9.30 -0.38 (-3.93%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$9.29 -0.01 (-0.11%)

As of 07/13/2026 04:10 PM Eastern

Compare

INFU vs. BBNX, CBLL, SIBN, SGP, and SSII

Should you buy InfuSystem stock or one of its competitors? MarketBeat compares InfuSystem with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with InfuSystem include Beta Bionics (BBNX), CeriBell (CBLL), SiBone (SIBN), Spyglass Pharma (SGP), and SS Innovations International (SSII). These companies are all part of the "medical equipment" industry.

How does InfuSystem compare to Beta Bionics?

Beta Bionics (NASDAQ:BBNX) and InfuSystem (NYSE:INFU) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

71.1% of InfuSystem shares are owned by institutional investors. 5.3% of Beta Bionics shares are owned by insiders. Comparatively, 10.8% of InfuSystem shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Beta Bionics had 3 more articles in the media than InfuSystem. MarketBeat recorded 3 mentions for Beta Bionics and 0 mentions for InfuSystem. Beta Bionics' average media sentiment score of 1.64 beat InfuSystem's score of 0.00 indicating that Beta Bionics is being referred to more favorably in the media.

Company	Overall Sentiment
Beta Bionics	Very Positive
InfuSystem	Neutral

Beta Bionics currently has a consensus target price of $20.10, suggesting a potential upside of 18.58%. InfuSystem has a consensus target price of $15.00, suggesting a potential upside of 61.29%. Given InfuSystem's stronger consensus rating and higher possible upside, analysts clearly believe InfuSystem is more favorable than Beta Bionics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Beta Bionics has a beta of 3.04, indicating that its stock price is 204% more volatile than the broader market. Comparatively, InfuSystem has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market.

InfuSystem has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beta Bionics	$100.25M	7.53	-$73.20M	-$1.51	N/A
InfuSystem	$142.40M	1.32	$870K	$0.38	24.47

InfuSystem has a net margin of 1.12% compared to Beta Bionics' net margin of -60.27%. InfuSystem's return on equity of 2.78% beat Beta Bionics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beta Bionics	-60.27%	-23.00%	-20.55%
InfuSystem	1.12%	2.78%	1.41%

Summary

InfuSystem beats Beta Bionics on 11 of the 17 factors compared between the two stocks.

How does InfuSystem compare to CeriBell?

CeriBell (NASDAQ:CBLL) and InfuSystem (NYSE:INFU) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation.

In the previous week, CeriBell had 5 more articles in the media than InfuSystem. MarketBeat recorded 5 mentions for CeriBell and 0 mentions for InfuSystem. CeriBell's average media sentiment score of 0.72 beat InfuSystem's score of 0.00 indicating that CeriBell is being referred to more favorably in the media.

Company	Overall Sentiment
CeriBell	Positive
InfuSystem	Neutral

CeriBell has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market. Comparatively, InfuSystem has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market.

CeriBell currently has a consensus price target of $22.20, indicating a potential upside of 13.73%. InfuSystem has a consensus price target of $15.00, indicating a potential upside of 61.29%. Given InfuSystem's higher possible upside, analysts clearly believe InfuSystem is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

InfuSystem has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CeriBell	$89.06M	8.32	-$53.41M	-$1.63	N/A
InfuSystem	$142.40M	1.32	$870K	$0.38	24.47

InfuSystem has a net margin of 1.12% compared to CeriBell's net margin of -63.51%. InfuSystem's return on equity of 2.78% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CeriBell	-63.51%	-38.19%	-30.92%
InfuSystem	1.12%	2.78%	1.41%

71.1% of InfuSystem shares are owned by institutional investors. 20.1% of CeriBell shares are owned by company insiders. Comparatively, 10.8% of InfuSystem shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

InfuSystem beats CeriBell on 10 of the 17 factors compared between the two stocks.

How does InfuSystem compare to SiBone?

SiBone (NASDAQ:SIBN) and InfuSystem (NYSE:INFU) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership.

InfuSystem has lower revenue, but higher earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$200.93M	3.94	-$18.90M	-$0.39	N/A
InfuSystem	$142.40M	1.32	$870K	$0.38	24.47

In the previous week, SiBone had 5 more articles in the media than InfuSystem. MarketBeat recorded 5 mentions for SiBone and 0 mentions for InfuSystem. SiBone's average media sentiment score of 0.18 beat InfuSystem's score of 0.00 indicating that SiBone is being referred to more favorably in the media.

Company	Overall Sentiment
SiBone	Neutral
InfuSystem	Neutral

SiBone has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market. Comparatively, InfuSystem has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market.

SiBone presently has a consensus target price of $23.00, suggesting a potential upside of 28.85%. InfuSystem has a consensus target price of $15.00, suggesting a potential upside of 61.29%. Given InfuSystem's higher probable upside, analysts plainly believe InfuSystem is more favorable than SiBone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

98.1% of SiBone shares are owned by institutional investors. Comparatively, 71.1% of InfuSystem shares are owned by institutional investors. 3.9% of SiBone shares are owned by insiders. Comparatively, 10.8% of InfuSystem shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

InfuSystem has a net margin of 1.12% compared to SiBone's net margin of -8.10%. InfuSystem's return on equity of 2.78% beat SiBone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SiBone	-8.10%	-9.56%	-7.06%
InfuSystem	1.12%	2.78%	1.41%

Summary

InfuSystem beats SiBone on 9 of the 16 factors compared between the two stocks.

How does InfuSystem compare to Spyglass Pharma?

InfuSystem (NYSE:INFU) and Spyglass Pharma (NASDAQ:SGP) are both small-cap medical equipment companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations.

InfuSystem has higher revenue and earnings than Spyglass Pharma. Spyglass Pharma is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InfuSystem	$142.40M	1.32	$870K	$0.38	24.47
Spyglass Pharma	N/A	N/A	N/A	-$6.41	N/A

InfuSystem has a net margin of 1.12% compared to Spyglass Pharma's net margin of 0.00%. InfuSystem's return on equity of 2.78% beat Spyglass Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InfuSystem	1.12%	2.78%	1.41%
Spyglass Pharma	N/A	N/A	N/A

In the previous week, Spyglass Pharma had 8 more articles in the media than InfuSystem. MarketBeat recorded 8 mentions for Spyglass Pharma and 0 mentions for InfuSystem. Spyglass Pharma's average media sentiment score of 0.31 beat InfuSystem's score of 0.00 indicating that Spyglass Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
InfuSystem	Neutral
Spyglass Pharma	Neutral

71.1% of InfuSystem shares are held by institutional investors. 10.8% of InfuSystem shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

InfuSystem presently has a consensus target price of $15.00, suggesting a potential upside of 61.29%. Spyglass Pharma has a consensus target price of $45.00, suggesting a potential upside of 126.13%. Given Spyglass Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Spyglass Pharma is more favorable than InfuSystem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Spyglass Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Summary

InfuSystem beats Spyglass Pharma on 8 of the 13 factors compared between the two stocks.

How does InfuSystem compare to SS Innovations International?

SS Innovations International (NASDAQ:SSII) and InfuSystem (NYSE:INFU) are both small-cap medical equipment companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

In the previous week, SS Innovations International had 9 more articles in the media than InfuSystem. MarketBeat recorded 9 mentions for SS Innovations International and 0 mentions for InfuSystem. SS Innovations International's average media sentiment score of 0.58 beat InfuSystem's score of 0.00 indicating that SS Innovations International is being referred to more favorably in the media.

Company	Overall Sentiment
SS Innovations International	Positive
InfuSystem	Neutral

InfuSystem has higher revenue and earnings than SS Innovations International. SS Innovations International is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SS Innovations International	$42.49M	17.14	-$12.13M	-$0.05	N/A
InfuSystem	$142.40M	1.32	$870K	$0.38	24.47

SS Innovations International currently has a consensus target price of $7.00, suggesting a potential upside of 92.31%. InfuSystem has a consensus target price of $15.00, suggesting a potential upside of 61.29%. Given SS Innovations International's higher possible upside, equities research analysts plainly believe SS Innovations International is more favorable than InfuSystem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SS Innovations International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

SS Innovations International has a beta of -1.96, indicating that its stock price is 296% less volatile than the broader market. Comparatively, InfuSystem has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market.

InfuSystem has a net margin of 1.12% compared to SS Innovations International's net margin of -20.69%. InfuSystem's return on equity of 2.78% beat SS Innovations International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SS Innovations International	-20.69%	-23.00%	-13.18%
InfuSystem	1.12%	2.78%	1.41%

71.1% of InfuSystem shares are owned by institutional investors. 10.8% of InfuSystem shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

InfuSystem beats SS Innovations International on 12 of the 16 factors compared between the two stocks.

Get InfuSystem News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INFU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INFU vs. The Competition

Export

Metric	InfuSystem	Surgical & medical instruments Industry	Medical Sector	NYSE Exchange
Market Cap	$187.69M	$43.47M	$7.05B	$23.46B
Dividend Yield	N/A	1.08%	2.68%	4.02%
P/E Ratio	155.03	19.13	27.12	31.08
Price / Sales	1.32	28.47	587.25	19.77
Price / Cash	12.79	18.86	29.22	18.64
Price / Book	3.77	9.23	10.89	4.77
Net Income	$870K	-$20.39M	$3.58B	$1.06B
7 Day Performance	-4.02%	-4.31%	-2.11%	-0.23%
1 Month Performance	1.75%	-1.74%	3.28%	-0.11%
1 Year Performance	65.78%	-9.47%	26.33%	16.46%

InfuSystem Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INFU InfuSystem	3.3608 of 5 stars	$9.30 -3.9%	$15.00 +61.3%	+60.3%	$187.69M	$142.40M	155.03	410
BBNX Beta Bionics	2.4297 of 5 stars	$15.67 -7.8%	$19.70 +25.7%	+33.8%	$757.55M	$100.25M	N/A	294	Analyst Forecast
CBLL CeriBell	1.941 of 5 stars	$19.45 -2.6%	$22.20 +14.1%	+21.0%	$757.34M	$89.06M	N/A	N/A
SIBN SiBone	2.6623 of 5 stars	$16.32 -3.3%	$23.00 +40.9%	+3.8%	$748.62M	$200.93M	N/A	350	News Coverage High Trading Volume
SGP Spyglass Pharma	1.967 of 5 stars	$22.26 +2.8%	$45.00 +102.2%	N/A	$744.22M	N/A	N/A	65	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:INFU) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

InfuSystem (INFU) Competitors

INFU vs. BBNX, CBLL, SIBN, SGP, and SSII

How does InfuSystem compare to Beta Bionics?

Summary

How does InfuSystem compare to CeriBell?

Summary

How does InfuSystem compare to SiBone?

Summary

How does InfuSystem compare to Spyglass Pharma?

Summary

How does InfuSystem compare to SS Innovations International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INFU vs. The Competition

InfuSystem Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

InfuSystem (INFU) Competitors

INFU vs. BBNX, CBLL, SIBN, SGP, and SSII

How does InfuSystem compare to Beta Bionics?

Do insiders and institutionals have more ownership in BBNX or INFU?

Does the media refer more to BBNX or INFU?

Do analysts recommend BBNX or INFU?

Which has more risk and volatility, BBNX or INFU?

Which has higher valuation and earnings, BBNX or INFU?

Is BBNX or INFU more profitable?

Summary

How does InfuSystem compare to CeriBell?

Does the media favor CBLL or INFU?

Which has more risk and volatility, CBLL or INFU?

Do analysts prefer CBLL or INFU?

Which has higher valuation & earnings, CBLL or INFU?

Is CBLL or INFU more profitable?

Do insiders & institutionals have more ownership in CBLL or INFU?

Summary

How does InfuSystem compare to SiBone?

Which has stronger earnings & valuation, SIBN or INFU?

Does the media favor SIBN or INFU?

Which has more volatility and risk, SIBN or INFU?

Do analysts recommend SIBN or INFU?

Do insiders & institutionals hold more shares of SIBN or INFU?

Is SIBN or INFU more profitable?

Summary

How does InfuSystem compare to Spyglass Pharma?

Which has stronger earnings & valuation, INFU or SGP?

Is INFU or SGP more profitable?

Does the media refer more to INFU or SGP?

Do insiders and institutionals have more ownership in INFU or SGP?

Do analysts prefer INFU or SGP?

Summary

How does InfuSystem compare to SS Innovations International?

Does the media favor SSII or INFU?

Which has preferable valuation & earnings, SSII or INFU?

Do analysts rate SSII or INFU?

Which has more volatility & risk, SSII or INFU?

Is SSII or INFU more profitable?

Do institutionals and insiders hold more shares of SSII or INFU?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INFU vs. The Competition

InfuSystem Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools